Source author record

An Vandebosch

An Vandebosch appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
2topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2020arXiv

A novel estimand to adjust for rescue treatment in clinical trials

The interpretation of randomised clinical trial results is often complicated by intercurrent events. For instance, rescue medication is sometimes given to patients in response to worsening of their disease, either in addition to the randomised treatment or in its place. The use of such medication complicates the interpretation of the intention-to-treat analysis. In view of this, we propose a novel estimand defined as the intention-to-treat effect that would have been observed, had patients on the active arm been switched to rescue medication if and only if they would have been switched when randomised to control. This enables us to disentangle the treatment effect from the effect of rescue medication on a patient's outcome, while avoiding the strong extrapolations that are typically needed when inferring what the intention-to-treat effect would have been in the absence of rescue medication. We develop an inverse probability weighting method to estimate this estimand under specific untestable assumptions, in view of which we propose a sensitivity analysis. We use the method for the analysis of a clinical trial conducted by Janssen Pharmaceuticals, in which chronically ill patients can switch to rescue medication for ethical reasons. Monte Carlo simulations confirm that the proposed estimator is unbiased in moderate sample sizes.

preprint2020arXiv

Efficient, Doubly Robust Estimation of the Effect of Dose Switching for Switchers in a Randomised Clinical Trial

Motivated by a clinical trial conducted by Janssen Pharmaceuticals in which a flexible dosing regimen is compared to placebo, we evaluate how switchers in the treatment arm (i.e., patients who were switched to the higher dose) would have fared had they been kept on the low dose. This in order to understand whether flexible dosing is potentially beneficial for them. Simply comparing these patients' responses with those of patients who stayed on the low dose is unsatisfactory because the latter patients are usually in a better health condition. Because the available information in the considered trial is too scarce to enable a reliable adjustment, we will instead transport data from a fixed dosing trial that has been conducted concurrently on the same target, albeit not in an identical patient population. In particular, we will propose an estimator which relies on an outcome model and a propensity score model for the association between study and patient characteristics. The proposed estimator is asymptotically unbiased if at least one of both models is correctly specified, and efficient (under the model defined by the restrictions on the propensity score) when both models are correctly specified. We show that the proposed method for using results from an external study is generically applicable in studies where a classical confounding adjustment is not possible due to positivity violation (e.g., studies where switching takes place in a deterministic manner). Monte Carlo simulations and application to the motivating study demonstrate adequate performance.